Convergent Dental has received the US Food and Drug Administration (FDA) clearance for its Solea, a CO2 laser system for ablation of hard tissue for caries removal and cavity preparation.
Claimed to be the first 9.3µm CO2 computer aided preparation (CAP) dental laser system, it cuts soft tissue precisely and cleanly than other traditional soft tissue lasers.
Using pulsed energy, and other patented technologies to safely and effectively cut hard tissue, the laser system performs incision, excision, vaporization, coagulation, and hemostasis of soft tissue in the oral cavity.
Convergent Dental CEO Michael Cataldo noted the FDA clearance for hard tissue indications will remove the anxiety traditionally associated with dentistry for patients for the first time.
"Our goal from the outset was to partner with the dental community to develop a computerized laser system for hard tissue preparation that they could master in a day and felt as easy and familiar as a drill but without the dread, and we’re very excited to have achieved that.
"We are also very pleased to have closed our funding rounds which will anchor our continued product research and development focus and market growth strategy," Cataldo added.
In February, the company received the FDA clearance for soft tissue indications.
Meanwhile, the company also announced the closure of Series A & B funding rounds totaling more than $13.5m.